Outsourcing in Clinical Trials Southern California24-25 September 2013, La Jolla, CA
The OCT team are proud to announce the arrival of the newest event in the series; Outsourcing in Clinical Trials Southern California. As a result of numerous requests to bring this series to the region, September 2013 will see the launch of a specifically tailored event catering to this life science hub.
With an agenda covering topics relevant to pharma, biotech, virtual and medical device companies, this event offers a unique opportunity to tailor your visit and take away the most valuable and relevant information and network with specific, high profile contacts.
Registration is now open for pharma and biotech executives. To receive more information, please e-mail - firstname.lastname@example.org (limited spaces available)
We are always happy to see photos taken at our events! If you have any you would like to submit, please email email@example.com The Arena Team
The OCT Southern California launch is being developed to allow you to entirely tailor your visit to meet your business needs and objectives. The event agenda is split so that the first day covers content relevant to biotech and pharma companies, and the second day of the event is divided into two, catering separately to virtual pharma and medical device manufacturers.
At Arena International we go to extreme lengths to get to know our audience and cater to their specific needs and wishes. The OCT team lives and breathes conferences in the biotech and pharma space, allowing us to create truly innovative and inspired events. Here are just 7 of the reasons to attend our most popular event series.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news.
We now have a brand new group for the Outsourcing in Clinical Trials series on LinkedIn! Join the group for great ways to network with sponsors, speakers and delegates.
OncoMed Pharmaceuticals has initiated a Phase Ib clinical trial of its Wnt-pathway-targeting antibody vantictumab (OMP-18R5) in combination with nab-paclitaxel (Abraxane) and gemcitabine in patients with Stage IV pancreatic cancer.
French pharmaceutical firm Sanofi has released results of a 24-week Phase IIIb clinical trial showing that Lyxumia (lixisenatide) met the primary endpoint of non-inferiority in blood sugar lowering (HbA1c) when given to patients either before breakfa…
US-based biopharmaceutical firm Lexicon Pharmaceuticals has released top-line results from an initial Phase II trial, designed to assess the use of its investigational drug LX1033 in diarrhea-predominant irritable bowel syndrome (IBS-d).
US-based biopharmaceutical firm Puma Biotechnology has released top line results from the I-SPY 2 Trial ('Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2') of its investigational drug PB272 (…
Denmark-based Novo Nordisk has announced that a Phase III trial of its investigational therapy IDegLira showed better control of blood sugar levels (HbA1c) compared with its own long-acting insulin Tresiba.